CheckMate 649: 1L nivo + chemotherapy improves OS
3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC
Biomarker analyses of the CheckMate 649 trial in GC/GEJC/EAC
Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020
Clinical Trials Updates for Gastric Cancer Patients Webinar
Part 2 - Nivolumab with chemotherapy in advanced previously untreated Gastric - Dr. Anant Ramaswamy
Update on the CheckMate649 trial in treatment-naïve GEA
Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting
Nivolumab chemotherapy combination treatment: CheckMate649 and ATTRACTION-4
Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study
29-month follow-up from CheckMate 648: nivolumab combination therapy in ESCC
Beyond the Horizon in Gastric Cancer: Updated Evidence on How Systemic Therapies Are Redefining Care
#ESMO21 Expert Video Report on immunotherapy in gastro-oesophageal cancer
Updates from CheckMate 040 in Asian HCC patients
Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications
33 First Line Therapy for HER2- PDL1+ GEA
Clinical Trials Updates for Gastric Cancer Patients
しっかり知りたい胃がん治療のこと:胃がんから知るがん治療の今、そして明日
Advances in adjuvant and 1L immune checkpoint blockade for gastric and esophageal cancer